コンテンツへスキップ
Merck
  • Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.

Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.

Nature communications (2014-09-16)
Wei Lu, Senthilkumar S Karuppagounder, Danielle A Springer, Michele D Allen, Lixin Zheng, Brittany Chao, Yan Zhang, Valina L Dawson, Ted M Dawson, Michael Lenardo
要旨

Mitophagy is a specialized form of autophagy that selectively disposes of dysfunctional mitochondria. Delineating the molecular regulation of mitophagy is of great importance because defects in this process lead to a variety of mitochondrial diseases. Here we report that mice deficient for the mitochondrial protein, phosphoglycerate mutase family member 5 (PGAM5), displayed a Parkinson's-like movement phenotype. We determined biochemically that PGAM5 is required for the stabilization of the mitophagy-inducing protein PINK1 on damaged mitochondria. Loss of PGAM5 disables PINK1-mediated mitophagy in vitro and leads to dopaminergic neurodegeneration and mild dopamine loss in vivo. Our data indicate that PGAM5 is a regulator of mitophagy essential for mitochondrial turnover and serves a cytoprotective function in dopaminergic neurons in vivo. Moreover, PGAM5 may provide a molecular link to study mitochondrial homeostasis and the pathogenesis of a movement disorder similar to Parkinson's disease.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
3,4-ジヒドロキシ-L-フェニルアラニン, ≥98% (TLC)
Sigma-Aldrich
カルボニルシアニド 3-クロロフェニルヒドラゾン, ≥97% (TLC), powder
USP
3,4-ジヒドロキシ-L-フェニルアラニン, United States Pharmacopeia (USP) Reference Standard
Supelco
レボドパ, Pharmaceutical Secondary Standard; Certified Reference Material
3,4-ジヒドロキシ-L-フェニルアラニン, European Pharmacopoeia (EP) Reference Standard
Supelco
4-tert-オクチルフェノールモノエトキシラート 溶液, 10 μg/mL in acetone, analytical standard
Sigma-Aldrich
MISSION® esiRNA, targeting human PGAM5
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Pgam5